These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 37809473)

  • 1. Paving the way for patient centricity in real-world evidence (RWE): Qualitative interviews to identify considerations for wider implementation of patient-reported outcomes in RWE generation.
    Maruszczyk K; McMullan C; Aiyegbusi OL; Keeley T; Wilson R; Collis P; Bottomley C; Calvert MJ
    Heliyon; 2023 Sep; 9(9):e20157. PubMed ID: 37809473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic review of guidance for the collection and use of patient-reported outcomes in real-world evidence generation to support regulation, reimbursement and health policy.
    Maruszczyk K; Aiyegbusi OL; Torlinska B; Collis P; Keeley T; Calvert MJ
    J Patient Rep Outcomes; 2022 Jun; 6(1):57. PubMed ID: 35652983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of real-world evidence in cancer drug funding decisions in Canada: a qualitative study of stakeholders' perspectives.
    Clausen M; Mighton C; Kiflen R; Sebastian A; Dai WF; Mercer RE; Beca JM; Isaranuwatchai W; Chan KKW; Bombard Y
    CMAJ Open; 2020; 8(4):E772-E778. PubMed ID: 33234584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world evidence: perspectives on challenges, value, and alignment of regulatory and national health technology assessment data collection requirements.
    Sievers H; Joos A; Hiligsmann M
    Int J Technol Assess Health Care; 2021 Feb; 37():e40. PubMed ID: 33622423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of real-world data and evidence for medical devices: a qualitative study of key informant interviews.
    Polisena J; Jayaraman G
    Int J Technol Assess Health Care; 2020 Dec; 36(6):579-584. PubMed ID: 33161916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.
    Orsini LS; Berger M; Crown W; Daniel G; Eichler HG; Goettsch W; Graff J; Guerino J; Jonsson P; Lederer NM; Monz B; Mullins CD; Schneeweiss S; Brunt DV; Wang SV; Willke RJ
    Value Health; 2020 Sep; 23(9):1128-1136. PubMed ID: 32940229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Comprehensive Framework for Evaluating the Value Created by Real-World Evidence for Diverse Stakeholders: The Case for Coordinated Registry Networks.
    Gressler LE; Marinac-Dabic D; Resnic FS; Williams S; Yang K; Weichold F; Avila-Tang E; Mack C; Coplan P; Panagiotou OA; Pappas G
    Ther Innov Regul Sci; 2024 Nov; 58(6):1042-1052. PubMed ID: 39060838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using patient-reported outcome measures during the management of patients with end-stage kidney disease requiring treatment with haemodialysis (PROM-HD): a qualitative study.
    Anderson NE; McMullan C; Calvert M; Dutton M; Cockwell P; Aiyegbusi OL; Kyte D
    BMJ Open; 2021 Aug; 11(8):e052629. PubMed ID: 34446501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RWE Framework: An Interactive Visual Tool to Support a Real-World Evidence Study Design.
    Xia AD; Schaefer CP; Szende A; Jahn E; Hirst MJ
    Drugs Real World Outcomes; 2019 Dec; 6(4):193-203. PubMed ID: 31741199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving transparency to build trust in real-world secondary data studies for hypothesis testing-Why, what, and how: recommendations and a road map from the real-world evidence transparency initiative.
    Orsini LS; Monz B; Mullins CD; Van Brunt D; Daniel G; Eichler HG; Graff J; Guerino J; Berger M; Lederer NM; Jonsson P; Schneeweiss S; Wang SV; Crown W; Goettsch W; Willke RJ
    Pharmacoepidemiol Drug Saf; 2020 Nov; 29(11):1504-1513. PubMed ID: 32924243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Evidence: Useful in the Real World of US Payer Decision Making? How? When? And What Studies?
    Malone DC; Brown M; Hurwitz JT; Peters L; Graff JS
    Value Health; 2018 Mar; 21(3):326-333. PubMed ID: 29566840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Real-World Evidence for Regulatory Approval and Coverage of Medical Devices: A Landscape Assessment.
    Timbie JW; Kim AY; Concannon TW
    Value Health; 2021 Dec; 24(12):1792-1798. PubMed ID: 34838277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of real-world evidence for oncology clinical decision making in emerging economies.
    Petracci F; Ghai C; Pangilinan A; Suarez LA; Uehara R; Ghosn M
    Future Oncol; 2021 Aug; 17(22):2951-2960. PubMed ID: 34044583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maximizing the Value of Real-World Data and Real-World Evidence to Accelerate Healthcare Transformation in China: Summary of External Advisory Committee Meetings.
    Sun F; Bedenkov A; Liu BC; Yang J; Xu JF; Ji L; Zhou M; Zhang S; Li X; Song Y; Chen P; Moreno C
    Pharmaceut Med; 2024 May; 38(3):157-166. PubMed ID: 38573457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Payer perceptions of the use of real-world evidence in oncology-based decision making.
    Brixner D; Biskupiak J; Oderda G; Burgoyne D; Malone DC; Arondekar B; Niyazov A
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1096-1105. PubMed ID: 34337998
    [No Abstract]   [Full Text] [Related]  

  • 17. Demonstrating that Real World Evidence Is Fit-For-Purpose to Support Labeling: Parallels to Patient Reported Outcomes in the Pursuit of Labeling Claims.
    Girman CJ; Ritchey ME; McNeill AM; Sundell KA; Meyer RJ
    Ther Innov Regul Sci; 2021 May; 55(3):561-567. PubMed ID: 33507517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Healthcare Claims Data to Generate Real-World Evidence on Patients With Drug-Resistant Epilepsy: Practical Considerations for Research.
    Stamas N; Vincent T; Evans K; Li Q; Danielson V; Lassagne R; Berger A
    J Health Econ Outcomes Res; 2024; 11(1):57-66. PubMed ID: 38425708
    [No Abstract]   [Full Text] [Related]  

  • 19. Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's RWE Data Working Group.
    Dai WF; de Oliveira C; Blommaert S; Pataky RE; Tran D; Aurangzeb Z; Kendell C; Folkins C; Somayaji C; Dowden J; Cheung W; Strumpf E; Beca JM; McClure C; Urquhart R; McDonald JT; Alvi R; Turner D; Peacock S; Denburg A; Mercer RE; Muñoz C; Parmar A; Tadrous M; Takhar P; Chan KKW; On Behalf Of The CanREValue Collaboration
    Curr Oncol; 2022 Mar; 29(3):2046-2063. PubMed ID: 35323365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The challenges and opportunities in using real-world data to drive advances in healthcare in East Asia: expert panel recommendations.
    Crane G; Lim JCW; Gau CS; Xie J; Chu L
    Curr Med Res Opin; 2022 Sep; 38(9):1543-1551. PubMed ID: 35786170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.